Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Colorcon
Merck
Express Scripts

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,427,402

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,427,402 protect, and when does it expire?

Patent 9,427,402 protects MULPLETA and is included in one NDA.

This patent has fourteen patent family members in nine countries.

Summary for Patent: 9,427,402
Title:Preparation for improving solubility of poorly soluble drug
Abstract: The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.
Inventor(s): Sakuma; Satoshi (Amagasaki, JP), Ueda; Hiroshi (Toyonaka, JP), Mashimo; Akira (Amagasaki, JP), Murazato; Hiroshi (Osaka, JP)
Assignee: Shionogi & Co. Ltd. (Osaka, JP)
Application Number:13/825,552
Patent Claim Types:
see list of patent claims
Use; Compound; Process; Dosage form;

Drugs Protected by US Patent 9,427,402

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,427,402

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2010-221000Sep 30, 2010
PCT Information
PCT FiledSeptember 29, 2011PCT Application Number:PCT/JP2011/072355
PCT Publication Date:April 05, 2012PCT Publication Number: WO2012/043709

International Family Members for US Patent 9,427,402

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112013007364   Start Trial
Canada 2813147   Start Trial
China 103228277   Start Trial
European Patent Office 2623100   Start Trial
Japan 2014141518   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Colorcon
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.